ESR1 and breast cancer: The mTOR inhibitor everolimus was recently approved by the Food and Drug Administration for treatment of aromatase inhibitor-resistant estrogen receptor positive breast cancer, and a number of PI3-kinase or Akt inhibitors are under active clinical investigation in breast cancer.